Androgenetic Alopecia in Fabry Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01295008|
Recruitment Status : Completed
First Posted : February 14, 2011
Last Update Posted : January 13, 2016
|Condition or disease|
Objectives: To test the hypothesis that adult males with classic form of Fabry disease have a significantly lower incidence of androgenic alopecia than matched controls.
Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls.
Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects.
Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
|Study Type :||Observational|
|Actual Enrollment :||107 participants|
|Official Title:||Androgenetic Alopecia in Fabry Disease|
|Study Start Date :||December 2010|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||October 2015|
|Patients with the classic form|
|Fabry disease and healthy controls|
- No and frontal only androgenetic alopecia [ Time Frame: 1 Year ]No and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
- Vertex only and frontal and vertex androgenetic alopecia. [ Time Frame: 1 Year ]No and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01295008
|United States, Texas|
|Baylor University Medical Center|
|Dallas, Texas, United States, 75246|
|Principal Investigator:||Raphael Schiffmann, MD||Baylor Research Institute|